Amylyx Pharmaceuticals Inc.’s oversubscribed, $135 million series C financing led by Viking Global Investors will help lay the groundwork for commercializing in Canada and Europe, as well as for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results